FluoGuide A/S (STO:FLUO)

Market Cap	639.26M
Revenue (ttm)	-703.14K
Net Income (ttm)	-51.97M
Shares Out	16.35M
EPS (ttm)	-3.81
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	19,317
Average Volume	9,294
Open	40.10
Previous Close	37.80
Day's Range	36.30 - 42.90
52-Week Range	29.10 - 57.00
Beta	0.76
RSI	47.25
Earnings Date	Nov 27, 2025

About FluoGuide

FluoGuide A/S, a clinical stage biotechnology company, focuses on developing drugs for surgical outcomes by making cancer fluorescent in Denmark. Its lead product candidate is FG001, which is in Phase IIa and IIb for the treatment of high-grade glioma; Phase II clinical trial for the treatment of lung cancer, and head and neck cancer. The company has a collaboration agreement with ZEISS Medical Technologies for the development of FG001 for tumor imaging and surgical margins assessment for head and neck cancer. FluoGuide A/S was incorporated in ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2018
• Employees: 8
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: FLUO

Financial Performance

In 2024, FluoGuide's revenue was 385,000, a decrease of -8.98% compared to the previous year's 423,000. Losses were -28.96 million, -24.54% less than in 2023.

Financial numbers in DKK